Interactions of Epidermal Growth Factor Receptor Inhibition with DNA damage in the treatment of gastrointestinal cancer
- đ¤ Speaker: Prof Daniel Hochhauser, University College London
- đ Date & Time: Tuesday 14 September 2010, 12:00 - 13:00
- đ Venue: CRI Lecture Theatre
Abstract
There has been extensive development of targeted therapies for treatment of cancer. These include antibodies and small molecules which inhibit pathways essential for cancer cell proliferation and metastasis. An important example is the epidermal growth factor receptor (EGFR) pathway which is the target of antibodies (cetuximab, panitumumab) and small molecules (gefitinib, erlotinib) used clinically. Although specific EGFR mutations found in lung cancer result in significant sensitivity to gefitinib and erlotinib, the response to single agents has been modest. Preclinical evaluation has suggested synergy between chemotherapy and radiation when combined with EGFR inhibition. However this has not generally translated into clinical benefit. In this presentation the possible mechanisms of these interactions will be outlined, together with suggestions for design of optimal combinations of EGFR inhibitors and chemotherapy, using gastrointestinal cancer as an example.
Series This talk is part of the Cambridge Oncology Seminar Series series.
Included in Lists
- All Talks (aka the CURE list)
- Biology
- Cambridge Oncology Seminar Series
- cancer
- CCC talks for website
- cri
- CRI Lecture Theatre
- CRUK CI Seminars
- Life Sciences
- Life Sciences
- ME Seminar
- MRC Cancer Unit Seminars
- my_list
- other talks
- PMRFPS's
- se393's list
- sfm36
Note: Ex-directory lists are not shown.
![[Talks.cam]](/static/images/talkslogosmall.gif)

Prof Daniel Hochhauser, University College London
Tuesday 14 September 2010, 12:00-13:00